4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $744,045 | -15.9% | 58,449 | +19.3% | 0.00% | 0.0% |
| Q2 2023 | $885,213 | +108249.2% | 48,988 | +3.1% | 0.00% | 0.0% |
| Q1 2023 | $817 | -22.5% | 47,501 | +0.1% | 0.00% | 0.0% |
| Q4 2022 | $1,054 | -99.7% | 47,443 | +4.6% | 0.00% | 0.0% |
| Q3 2022 | $365,000 | +25.9% | 45,373 | +9.1% | 0.00% | – |
| Q2 2022 | $290,000 | -45.4% | 41,585 | +18.5% | 0.00% | -100.0% |
| Q1 2022 | $531,000 | -21.2% | 35,097 | +14.3% | 0.00% | 0.0% |
| Q4 2021 | $674,000 | +1.8% | 30,715 | +25.2% | 0.00% | 0.0% |
| Q3 2021 | $662,000 | +189.1% | 24,538 | +158.1% | 0.00% | – |
| Q2 2021 | $229,000 | -9.8% | 9,507 | +62.3% | 0.00% | – |
| Q1 2021 | $254,000 | – | 5,856 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |